World Federation of Hemophilia / Fédération mondiale de l'hémophilie/LinkedIn
Oct 18, 2025, 11:15
Gene Therapy Data at Risk – WFH Advocates for Global Preservation Through GTR
World Federation of Hemophilia / Fédération mondiale de l’hémophilie posted on LinkedIn:
” Nearly 400 people with hemophilia joined Gene Therapy trials, sharing their data to help future generations. If companies do not commit to preserve Gene Therapy data in one global database, that data becomes far less useful. The WFH Gene Therapy Registry (GTR) offers a global solution to safeguard this data and honor those contributions.
Read more about why data preservation is both a scientific and ethical imperative.”
Stay updated with Hemostasis Today.
-
Mar 6, 2026, 16:51Priya Reehal: Highlighting The Central Role of Nurses in Cardio-Oncology
-
Mar 6, 2026, 16:50Rainer Kaiser: Blinatumomab Shows Remarkable Response in Multi-Refractory ITP and APS
-
Mar 6, 2026, 16:18Laila Shalabi: Clopidogrel, Aspirin, and the Role of PPIs in Coronary Artery Disease
-
Mar 6, 2026, 16:17Paul McKenzie: The Value of Gene Therapy in Bleeding Disorders
-
Mar 6, 2026, 16:15Basma El Homasany: The ‘Little Brain’ of the Heart and Its Role in Health
-
Mar 6, 2026, 16:14Jamal Rana: Family History and Polygenic Risk for Coronary Heart Disease
-
Mar 6, 2026, 15:43Kristy Ainslie: Breaking Down the Discovery and FDA Approval of Drug Carriers
-
Mar 6, 2026, 15:18Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
-
Mar 6, 2026, 15:09Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis